Eight otherwise healthy women aged 17 to 38 years with endometriosis were treated with 2 mg of the progestin dienogest daily for 24 weeks. Blood glucose and plasma insulin were measured prior to and during an intravenous glucose tolerance test before and after 1, 3 and 6 months use of the oral progestin. There were no significant changes in fasting glucose and in glucose levels after the glucose load during the therapy though the fasting glucose levels tended to be higher under dienogest. The basal insulin values remained unchanged but the insulin response was slightly insignificantly increased after 10 and 20 minutes following glucose application depending on the duration of therapy. The data suggest that 2 mg dienogest administered daily has no or only a very slight influence on carbohydrate metabolism.
A prospective study was made to investigate the carbohydrate metabolic effects of the sequential-type oral contraceptive in form of a weekly pill with 0.6 mg ethinylestradiol-sulfonate soft gelatin capsules and 10 mg norethisterone acetate. Blood glucose and plasma insulin levels were measured during an intravenous glucose tolerance test in 17 nondiabetic healthy women. Each woman was tested before and after twelve months of drug use. There were no changes neither in average fasting blood glucose nor in glucose assimilation after intake of ethinylestradiol-sulfonate. At twelve months there were significant elevations of basal as well as reactive insulin levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.